Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
T. Rautenberg, U. Siebert, D. Arnold, J. Bennouna, S. Kubicka, S. Walzer & C. Ngoh. (2014) Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. Journal of Medical Economics 17:2, pages 99-110.
Read now
Read now
Chan Shen, Chun-Ru Chien, Daniel M Geynisman, Fabrice Smieliauskas & Ya-Chen T Shih. (2014) A review of economic impact of targeted oral anticancer medications. Expert Review of Pharmacoeconomics & Outcomes Research 14:1, pages 45-69.
Read now
Read now
A Vergnenègre, I Borget & C Chouaid. (2013) Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents. ClinicoEconomics and Outcomes Research 5, pages 137-141.
Read now
Read now
Articles from other publishers (6)
Weiwei Liu, Chao Zhang, Hui Cao, Dai Shi, Shanshan Zhao, Ting Liang & Guihua Hou. (2019) Radioimmunoimaging of 125I‑labeled anti‑CD93 monoclonal antibodies in a xenograft model of non‑small cell lung cancer. Oncology Letters.
Crossref
Crossref
Sikander Ailawadhi, Maral DerSarkissian, Mei Sheng Duh, Marie-Hélène Lafeuille, George Posner, Stephen Ralston, Erin Zagadailov, Abbie Ba-Mancini & Robert Rifkin. (2019) Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. Clinical Therapeutics 41:3, pages 477-493.e7.
Crossref
Crossref
Adam Bohr, Thais Nascimento, Necati Harmankaya, Johan Weisser, Yingya Wang, Holger Grohganz, Thomas Rades & Korbinian Löbmann. (2019) Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Molecules 24:2, pages 266.
Crossref
Crossref
Davide Paolini, Marcello Tiseo, Federica Demma, Gianluca Furneri, Matteo Dionisi, Marlene Akkermans & Antonio Marchetti. (2018) Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non–Small-cell Lung Cancer: Clinical and Budget Effect. Clinical Lung Cancer 19:5, pages e735-e743.
Crossref
Crossref
Maria Rita Migliorino, Antonio Santo, Giampiero Romano, Diego Cortinovis, Domenico Galetta, Oscar Alabiso, Giacomo Cartenì, Sabrina Vari, Gianpiero Fasola, Antonio Pazzola, Dario Giuffrida, Alberto Zaniboni, Alberto Caprioli, Flavia Longo, Valentina Acciai & Filippo de Marinis. (2017) Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. Journal of Cancer Research and Clinical Oncology 143:5, pages 783-791.
Crossref
Crossref
Sergio Iannazzo, Chiara Distante, Stefania Lopatriello & Roberto Bordonaro. (2017) A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 4:1, pages grhta.5000274.
Crossref
Crossref